Venoruton® (Venoruton®)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Similar drugsTo uncover
Dosage form: & nbspcapsules
Composition:

Each capsule contains:

active substance: hydroxyethylrutosides 300 mg.

Excipients: macrogol-6000 9.00 mg, empty hard gelatin capsule (gelatin about 63,0097 mg, water 11,02 mg, titanium dioxide about 1.50 mg, iron oxide oxide yellow about 0.47 mg).

The capsule is printed with black ink, the capsule contains trace amounts of ink.

Main Ingredients of Print Ink: shellac, iron dye oxide black, n-butanol, water, propylene glycol, isopropanol.

Description:Gelatine matt capsules are yellow-beige without a smell with the inscription "Venoruton 300", the contents of the capsules are powder from yellow to brownish-yellow color without a smell.
Pharmacotherapeutic group:Angioprotective agent
ATX: & nbsp
  • Rutozid
    • Pharmacodynamics:

    Derivative routine. Acts mainly on capillaries and veins. Strengthens the walls of blood vessels and capillaries and increases their tone. Helps improve blood circulation. Reduces the pores between endothelial cells by modifying a fibrous matrix located between endothelial cells. Inhibits aggregation and increases the degree of deformability of erythrocytes, has anti-inflammatory effect.

    With chronic venous insufficiency, Venoruton® reduces the severity of edema, pain, seizures,trophic disorders, varicose ulcers.

    It alleviates the symptoms associated with hemorrhoids: pain, itching and bleeding.

    Thanks to the beneficial effect of Venoruton® on the permeability and resistance of the capillary walls, the drug helps slow the development of diabetic retinopathy.

    In addition, the effect of Venoruton® on the rheological properties of blood contributes to the prevention of retinal microtrombosis.

    Pharmacokinetics:

    After oral administration, the maximum concentration in the blood plasma is reached within 2-9 hours. Within 40 hours the concentration of the drug remains detectable, its decrease occurs bi-exponentially. Binding to plasma proteins is 27-29%. Hydroxyethyl rutozides and their glucuronated metabolites are excreted mainly with bile, 3-6% are excreted by the kidneys in 48 hours. The half-life of hydroxyethylrutosides can vary from 13.5 to 25.7 hours, but for each person its value is relatively constant.

    Indications:

    - Chronic venous insufficiency, post-phlebitis syndrome, trophic disorders in varicose veins and trophic ulcers with symptoms such as: swelling, pain, cramps, paresthesia and feeling of heaviness in the legs.

    - at as an auxiliary treatment for lymphostasis, after sclerotherapy of veins and removal of varicose veins;

    - hemorrhoids (pain, exudation, itching and bleeding);

    - as an auxiliary treatment for retinopathy in patients with diabetes mellitus, arterial hypertension and atherosclerosis.

    Contraindications:

    Hypersensitivity to rutozides or other components of the drug.

    Pregnancy (I trimester), children under 18 years.

    Carefully:With hepatic, renal or cardiac insufficiency.
    Pregnancy and lactation:

    In experimental studies, teratogenic or other undesirable effects on the fetus.

    With breast milk, only minor amounts of the drug, which is not of clinical significance.

    The appointment of Venoruton ® inside during pregnancy from the second trimester, as well as during lactation, If the expected benefit for the mother exceeds the possible risk for the fetus.

    Dosing and Administration:

    Inside, with food. Capsules swallow whole, washed down with water.

    With chronic venous insufficiency, post-phlebitis syndrome, trophic disorders in varicose veins and trophic ulcers: at the initial stage of treatment (during the first 2 weeks) take 1 capsule of Venoruton ® 2-3 times a day (not more than 3 capsules per day). Further treatment is either continued for 2-3 months at the same dose as maintenance therapy, or discontinued.

    The minimum maintenance dose is 1 capsule 2 times a day. At the same time, the achieved therapeutic effect is maintained for at least 4 weeks. The minimum course of treatment, during which the effect usually develops, is 2 weeks.

    To maintain results, it is necessary to carry out 2 courses of treatment per year.

    With lymphostasis (along with bandaging of elastic bandages), also after sclerotherapy of veins and removal, varicose veins: the recommended dose is 10 capsules per day: 3 capsules in the morning and in the evening and 4 capsules at night for up to 6 months.

    To eliminate the symptoms of hemorrhoids: RThe recommended dose is 1 capsule 2-3 times a day (no more than 3 capsules per day) until symptoms are eliminated, usually within 28 days.

    With diabetic retinopathy, arterial hypertension and atherosclerosis (as an auxiliary therapy): 2-3 capsules 2-3 times a day, not more than 3000 mg per day, for 2 months.

    Side effects:

    Disorders from the immune system: very rarely (<1/10000): anaphylactoididenal reactions, hypersensitivity reactions.

    Disorders from the nervous system: very rarely (<1/10000): dizziness, headache.

    Vascular disorders: very rarely (<1/10000): "tides" of blood to face.

    Disturbances from the digestive system: rarely (> 1/10 000, <1/1000): gastrointestinal disorders, bloating, diarrhea, abdominal pain, stomach discomfort, digestive disorders.

    Skin and subcutaneous tissues: rarely (> 1/10 000, <1/1000): skin rash, itching, hives.

    General disorders: very rarely (<1/10 000): weakness.

    Overdose:No cases of overdose accompanied by clinical symptoms have been reported.
    Interaction:

    There were no reports of clinically significant interactions with other medicinal products.

    The action can be enhanced with simultaneous intake of ascorbic acid.

    Special instructions:

    If the severity of the symptoms of the disease does not decrease during the period of the drug use, you should consult a doctor.

    Effect on the ability to drive transp. cf. and fur:

    It was not reported on the effect of the drug on the ability to drive and work with machinery.

    Form release / dosage:Capsules, 300 mg.
    Packaging:

    For 10 capsules in a blister of PVC / PVDX or PVC / PE / PVDX in combination with aluminum foil.

    By 2 or 5 blisters together with instructions for use are placed in a cardboard box.

    Storage conditions:

    In a dry place, at a temperature of no higher than 30 ° C.

    Keep out of the reach of children.

    Shelf life:

    5 years.

    Do not use after the expiry date indicated on the package.

    Terms of leave from pharmacies:Without recipe
    Registration number:P N008948 / 01
    Date of registration:01.08.2011 / 25.04.2016
    Expiration Date:Unlimited
    The owner of the registration certificate:GlaxoSmithKline Helsker, ZAO GlaxoSmithKline Helsker, ZAO Russia
    Manufacturer: & nbsp
    Information update date: & nbsp09.03.2016
    Illustrated instructions
      Instructions
      Up